Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 16
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT05641259 | A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML | ||
| NCT06126861 | The Mass Balance Study of LP-168 in Healthy Subjects | ||
| NCT07189065 | A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma | ||
| NCT07609823 | A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL | ||
| NCT05025358 | A Study of LP-118 in Patients With Advanced Tumors | ||
| NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | ||
| NCT05716087 | A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma | ||
| NCT04993690 | A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma | ||
| NCT07374224 | A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet | ||
| NCT07570017 | A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | ||
| NCT05917964 | A Food Effect Study of LP-168 Tablets in Healthy Subjects | ||
| NCT04356846 | A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma | ||
| NCT05130567 | A Study of LP-128 Capsules in Healthy Subjects | ||
| NCT05432713 | A Study of LP-168 in Healthy Volunteers | ||
| NCT06251180 | Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma | ||
| NCT07377578 | A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma |
